CC-90005 is a potent, selective and orally active inhibitor of protein kinase C-θ (PKC-θ) , with an IC 50 of 8 nM. CC-90005 shows selectivity for PKC-θ over PKC-δ (IC 50 =4440 nM). CC-90005 can inhibit T cell activation by inhibiting IL-2 expression In Vitro CC-90005 shows the exquisite selectivity of CC-90005, with IC 50 s for all other family members of >3 μM. CC-90005 is a moderate inhibitor of both CYP2C9 (IC 50 =8 μM) and CYP2C19 (IC 50 =5.9 μM) in human liver microsomes. CC-90005 inhibits IL-2 expression in LRS_WBC human PBMCs, with an IC 50 of 0.15 μM. CC-90005 (1-10 μM; 24 h) inhibits T cell proliferation in PBMCs by 51% at 1 μM and 88% at 3 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo CC-90005 (3-30 mg/kg; p.o. twice daily for 4 days) significantly reduces the popliteal lymph node (PLN) size in a model of chronic T cell activation . CC-90005 (100 mg/kg; a single p.o.) significantly inhibits plasma and spleen IL-2 release by 51 and 54%, respectively . CC-90005 exhibits reasonable oral bioavailability (66 and 46%) and C max (1.18 and 1.2 μM) following oral administration (10 and 3 mg/kg) in rat and dog, respectively . CC-90005 exhibits the mean residence time (0.52 and 2.0 h), CL (69.1 and 20.5 mL/min/kg) and Vss (2.11 and 2.44 L/kg) following intravenous administration (2 and 1 mg/kg) in rat and dog, respectively . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: B6D2F1 mice (20 g) were injected with allogeneic spleen cells Dosage: 3, 10, 30 mg/kg Administration: P.o. twice daily for 4 days Result: Inhibited PLN size by 45 and 38% at doses of 10 and 30 mg/kg, respectively. Form:Solid IC50& Target:PKCθ 8 nM (IC 50 )